Process for treating a biological organism

• US 20060034943A1
• Filed: 10/11/2005
• Published: 02/16/2006
• Est. Priority Date: 10/31/2003
• Status: Abandoned Application

• Current Assignee: Technology Innovations, LLC
• Original Assignee: Technology Innovations, LLC
• Inventors: Tuszynski, Jack
• Application Number:
  US11/246,307
• Publication Number:
  US 20060034943A1
• Time in Patent Office: Days
• US Class Current: 424/649
• CPC Class Codes: A61K 41/0004 Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• CPC Class Codes: A61K 47/6921 the form being a particulate, a powder, an adsorbate, a bead or a sphere
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

A biological organism suffering from cancer can be treated by administering a cancer cell cycle arresting drug; optionally administering a microtubule stabilizing agent; and exposing the cell cycle arrested cells to mechanical vibrational energy. The method selectively induces apoptosis in cancer cells.

Claims

1. A process for treating a biological organism, comprising the steps of:

(a) administering a cell cycle arresting drug to said organism, thereby producing synchronized cells within such organism,

(b) administering a microtubule stabilizing drug to said organism, thereby producing synchronized cells whose microtubules have been stabilized within said organism, and

(c) contacting said synchronized cells whose microtubules have been stabilized with mechanical vibrational energy.

2. The process as recited in claim 1, wherein said mechanical vibrational energy has an excitation source frequency in the range of from about 1 hertz to about 10 Gigahertz.

3. The process as recited in claim 1, wherein said cell cycle arresting drug synchronizes tumor cells with respect to cell cycle progression.

4. The process as recited in claim 3, wherein said cell cycle arresting drug is selected from the group consisting of gemcitabine, cisplatin, carboplatin, cyclophosphamide, topoisomerase inhibitor, etoposide, 5-fluoroacil, doxorubicin, methotrexate, hydroxyurea, 3′

-azido-3′

-deoxythymidine, and mixtures thereof.

5. The process as recited in claim 3, wherein said cell cycle arresting drug is gemcitabine.

6. The process as recited in claim 1, wherein said cell cycle arresting drug synchronizes said cells in metaphase.

7. The process as recited in claim 1, wherein said cell cycle arresting drug synchronizes said cells in anaphase.

8. The process as recited in claim 6, wherein at least about 30 percent of said cells are synchronized in metaphase.

9. The process as recited in claim 6, wherein at least about 50 percent of said cells are synchronized in metaphase.

10. The process as recited in claim 6, wherein at least about 70 percent of said cells are synchronized in metaphase.

11. The process as recited in claim 1, wherein said mechanical vibrational energy is ultrasound.

12. The process as recited in claim 11, wherein said synchronized cells are contacted with said ultrasound only after at least 25 minutes after said cell cycle arresting drug has been administered to said organism.

13. The process as recited in claim 11, wherein said synchronized cells are contacted with said ultrasound only after at least 60 minutes after said cell cycle arresting drug has been administered to said organism.

14. The process as recited in claim 11, wherein said synchronized cells are contacted with said ultrasound only after at least 240 minutes after said cell cycle arresting drug has been administered to said organism.

15. The process as recited in claim 11, wherein said synchronized cells are contacted with said ultrasound only after at least 48 hours after said cell cycle arresting drug has been administered to said organism.

16. The process as recited in claim 11, wherein said microtubule stabilizing drug is a laulimalidge microtubule stabilizing agent.

17. The process as recited in claim 11, wherein said microtubule stabilizing drug is a coumarin compound.

18. The process as recited in claim 11, wherein said ultrasound has a frequency of from about 270 to about 420 kilohertz.

19. The process as recited in claim 11, wherein said ultrasound has an intensity of from about 10 to about 30 watts per square meter.

20. The process as recited in claim 11, wherein said microtubule stabilizing drug is paclitaxel.

21. The process as recited in claim 11, wherein said ultrasound has a frequency of from about 50 megahertz to about 2 gigahertz.

22. The process as recited in claim 11, wherein said ultrasound has a frequency of from about 100 megahertz to about 1 gigahertz.

23. The process as recited in claim 11, wherein the power of said ultrasound is at least about 0.01 watts per square meter.

24. The process as recited in claim 11, wherein the power of said ultrasound is at least about 0.1 watts per square meter.

25. The process as recited in claim 11, wherein said ultrasound has a frequency of form about 100 kilohertz to about 500 kilohertz.

26. The process as recited in claim 11, wherein said ultrasound has a frequency of from about 110 to about 200 kilohertz.

27. The process as recited in claim 11, wherein said ultrasound has a frequency of from about 130 to about 170 kilohertz.

28. The process as recited in claim 11, wherein the power of said ultrasound is from about 1 to about 30 watts per square meter.

29. The process as recited in claim 11, wherein the power of said ultrasound is from about 5 to about 15 watts per square meter.

30. A process for initiating apoptosis in a cancer cell comprising:

(a) contacting the cell with a cell cycle arresting drug; and

(b) contacting said cell with mechanical vibrational energy.

31. The process of claim 30, wherein the cell cycle arresting drug is selected from the group consisting of:

gemcytabine, cisplatin, carboplatin, cyclophosphamide, topoisomerase inhibitor, etoposide, 5-fluorouracil, doxorubicin, methotrexate, hydroxyurea, and 3′

-azido-3′

-deoxythymidine.

32. The process of claim 30, wherein the mechanical vibrational energy is ultrasound energy having a frequency of about 50 megahertz to about 2 gigahertz.

33. The process of claim 30, wherein the exposure to mechanical vibrational energy is repeated or sustained over a period of at least one typical cell cycle.

34. The process of claim 30, wherein the step of contacting the cell with mechanical vibrational energy is repeated or sustained over a period of at least one typical cell division.

35. The process of claim 30, further comprising a step of synchronizing tubulin assembly in the cell.

36. The process of claim 35, wherein the step of synchronizing tubulin assembly is effected by exposing the cell to a microtubule stabilizing agent and/or radiation, and the step is performed prior to contacting the cell with mechanical vibrational energy.

37. The process of claim 36, wherein the microtubule stabilizing agent is selected from the group consisting of taxanes, coumarins, and combinations thereof.

38. A method for treating a patient suffering from cancer comprising administering to said patient an amount of a cell cycle arresting drug sufficient to synchronize cell cycles of a plurality of cancer cells in said patient;

and subjecting said cells to mechanical vibrational energy.

39. The method of claim 38, wherein the cell cycle arresting drug is selected from the group consisting of:

gemcytabine, cisplatin, carboplatin, cyclophosphamide, topoisomerase inhibitor, etoposide, 5-fluorouracil, doxorubicin, methotrexate, hydroxyurea, and 3′

-azido-3′

-deoxythymidine.

40. The method of claim 38, wherein the mechanical vibrational energy is ultrasound energy having a frequency of about 50 megahertz to about 2 gigahertz.

41. The method of claim 38, wherein the exposure to mechanical vibrational energy is repeated or sustained over a period of at least one typical cell cycle.

42. A method of treating a patient suffering from cancer comprising administering to said patient an amount of a cell cycle arresting drug sufficient to synchronize cell cycles of a plurality of cancer cells in the patient;

administering to the patient a microtubule stabilizing agent; and

exposing the patient to mechanical vibrational energy.

43. The method of claim 42, wherein the microtubule stabilizing agent is selected from the group consisting of:

taxanes, magnetic taxanes;

coumarins, magnetic coumarins, and combinations thereof.

44. The method of claim 42, wherein the microtubule stabilizing agent is selected from the group consisting of paclitaxel, docetaxel, magnetic derivatives thereof, and combinations thereof.

45. The method of claim 42, wherein the cell cycle arresting drug is selected from the group consisting of:

gemcytabine, cisplatin, carboplatin, cyclophosphamide, topoisomerase inhibitor, etoposide, 5-fluorouracil, doxorubicin, methotrexate, hydroxyurea, and 3′

-azido-3′

-deoxythymidine.

46. The method of claim 42, wherein the cell cycle arresting drug is gemcytabine and the microtubule stabilizing agent is a taxane, a coumarin, magnetic derivatives thereof, and combinations thereof.

47. The method of claim 42, wherein the mechanical vibrational energy is ultrasound energy having a frequency of about 50 megahertz to about 2 gigahertz.

48. The method of claim 42, wherein exposure to mechanical vibrational energy is repeated or sustained over a period of at least one typical cell cycle.

49. The method of claim 42, wherein exposure to mechanical vibrational energy is performed at least 60 minutes after administration of the cell cycle arresting drug.

50. The method of claim 42, wherein the microtubule stabilizing agent is administered from a drug eluting implant.

51. The method of claim 50, wherein the implant is a drug eluting stent.

52. A process for treating a patient suffering from cancer comprising administering to said patient an amount of a cell cycle arresting drug sufficient to synchronize cell cycles of a plurality of the cancer cells in said patient;

administering to said patient radiation therapy sufficient to stabilize microtubule assembly in said cancer cells; and

subjecting said cancer cells to mechanical vibrational energy.

53. A method of treating a patient suffering from cancer comprising administering to said patient a cancer cell cycle arresting amount of gemcytabine;

administering a microtubule stabilizing agent selected from the group consisting of taxanes, coumarins, magnetic derivatives thereof, and combinations thereof; and

exposing the patient to mechanical vibrational energy of frequency of about 50 megahertz to about 2 gigahertz.

54. The method of claim 53, wherein the microtubule stabilizing agent is selected from the group consisting of paclitaxel, docetaxel, magnetic derivatives thereof, and combinations thereof.

55. A method of treating a patient suffering from cancer comprising administering to said patient an amount of a cell cycle arresting drug sufficient to synchronize cell cycles of a plurality of cancer cells in the patient;

administering to the patient a magnetic microtubule stabilizing agent;

applying a localized magnetic field to increase the concentration of magnetic microtubule stabilizing agent at a predetermined location in the patient; and

exposing the patient to mechanical vibrational energy.

56. The method of claim 55, wherein the magnetic microtubule stabilizing agent is a magnetic taxane or a magnetic coumarin.

57. The method of claim 55, wherein the mechanical vibrational energy is ultrasound energy of frequency of about 50 megahertz to about 2 gigahertz.

58. The method of claim 57, wherein the ultrasound energy is administered to the patient by an intracorporeal device.